Cardiogenic Shock: Clinical Management, Outcomes and Future Directions

Q: What is the clinical evidence from this study?

Study design: Review. Population: Cardiogenic shock. Intervention: Pharmacological therapies (vasopressors, inotropes), mechanical circulatory support (IABP, VA-ECMO, Impella), and emergency revascularisation (PCI, CABG).

Q: What does this research mean for the field?

Cardiogenic shock management relies on early culprit-lesion revascularisation and selective Impella CP support, whereas routine IABP and early VA-ECMO fail to reduce 30-day mortality in AMI-CS. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Aaqil Ahmad Aubdool; A Sullivan; Daniel A. Jones; Anthony Mathur; Alastair Proudfoot; Krishnaraj S. Rathod

doi:10.3390/jcdd13040156

March 31, 2026Journal of Cardiovascular Development and DiseaseOpen Access

Cardiogenic Shock: Clinical Management, Outcomes and Future Directions

View Full Paper

Ask AI

Bookmark

Share

Figures

Why the study?

Cardiogenic shock is a life-threatening condition resulting in hypoperfusion, end-organ failure, and death, prompting an examination of current treatments, management challenges, healthcare burdens, and future clinical directions.

Key Points

To review the pathophysiology, current clinical interventions, epidemiological outcomes, and emerging diagnostic and therapeutic innovations in cardiogenic shock.
Narrative review evaluating trial and registry evidence for pharmacotherapies, mechanical circulatory support, and emergency revascularisation strategies.
Assessed epidemiological trends, healthcare resource utilization within health systems like the UK National Health Service, and future roles for artificial intelligence and wearable monitors.
In the ESC-HF-LT registry of 6629 heart failure patients, cardiogenic shock carried a 36.1% in-hospital mortality rate, with 49% of all in-hospital deaths occurring within the first 24 hours and a 1-year mortality rate of 54.0%.
Analysis of over 1.2 million hospitalisations between 2004 and 2018 revealed incidence increased from 122 to 408 per 100,000 (P trend < 0.001), while adjusted in-hospital mortality declined from approximately 49% to 37%.
A cohort of 9789 intensive care unit patients with acute myocardial infarction-related shock demonstrated high post-discharge morbidity, with 42% requiring a higher level of care and 47.5% readmitted within one year.

Structured PICO

P

Population

Patients with cardiogenic shock, most commonly occurring following acute myocardial infarction or acute decompensated heart failure.

I

Intervention

Multifaceted clinical management including vasoactive medications (noradrenaline, dobutamine, milrinone, vasopressin, angiotensin II, levosimendan), mechanical circulatory support (intra-aortic balloon pump [IABP], veno-arterial extracorporeal membrane oxygenation [VA-ECMO], microaxial flow pumps [Impella CP, Impella 5.5]), and emergency revascularisation (culprit-lesion PCI or CABG).

Limitations

Detailed cost analyses of cardiogenic shock management and advanced mechanical circulatory support are scarce in the UK.
Robust randomised controlled trial data for non-adrenergic vasopressors and optimal antiplatelet strategies in pure cardiogenic shock remain limited.
Heterogeneity of cardiogenic shock populations and lack of standardised clinical definitions have limited the success of clinical trials.
Lack of comprehensive UK-specific national cost data for cardiogenic shock and mechanical circulatory support devices
Limited randomized controlled trial evidence for non-adrenergic vasopressors and specific mechanical circulatory support devices across diverse shock etiologies
Challenges in adopting AI and wearable technologies due to suboptimal image quality, model interpretability, false positive alerts, and retrospective training datasets

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This comprehensive narrative review synthesizes current evidence on pharmacological, mechanical, and revascularisation strategies for cardiogenic shock, highlighting UK healthcare resource challenges and future directions in biomarker subphenotyping, AI, and trial design.

Abstract

Cardiogenic shock is a life-threatening condition caused by the heart’s sudden inability to pump sufficient blood to maintain adequate tissue perfusion, most commonly occurring following a myocardial infarction or acute decompensated heart failure. The resultant hypoperfusion can quickly progress to end-organ failure and ultimately death if not treated urgently. This review explores the management of cardiogenic shock, highlighting current treatments, their effectiveness, and the challenges faced by healthcare providers. It looks at both pharmacological therapies and devices used for cardiac support, including mechanical circulatory support and emergency revascularisation procedures to restore blood flow. We also examine how different stages of shock affect survival and how new technologies including artificial intelligence and wearable monitors could help detect and treat this condition earlier. In addition, this review discusses the significant pressure that cardiogenic shock places on healthcare provision, including the typical financial cost of treatment in the UK, resource utilisation and regional disparities. Finally, we outline future directions for trial design, better prevention, more rapid diagnosis and improved treatments that could improve morbidity and mortality.

Cite This Study

Aubdool et al. (2026) conducted a review in Cardiogenic shock. Pharmacological therapies (vasopressors, inotropes), mechanical circulatory support (IABP, VA-ECMO, Impella), and emergency revascularisation (PCI, CABG) was evaluated.

synapsesocial.com/papers/69cf5db15a333a821460ba53 https://doi.org/10.3390/jcdd13040156

View Full Paper

Ask AI

Bookmark

Share

Cardiogenic Shock: Clinical Management, Outcomes and Future Directions

Figures

Key Points

Structured PICO

Limitations

Discussion

Implication

Abstract

Cite This Study

Cardiogenic Shock: Clinical Management, Outcomes and Future Directions

Figures

Key Points

Structured PICO

Limitations

Discussion

Implication

Abstract

Cite This Study

Keep reading

Keep reading